This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CMRX Chimerix (CMRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisFDA EventsInsider TradesOwnershipTrendsBuy This Stock About Chimerix Stock (NASDAQ:CMRX) Get Chimerix alerts:Sign Up Key Stats Today's Range$8.54▼$8.5450-Day Range$8.54▼$8.5452-Week Range$0.75▼$8.55VolumeN/AAverage Volume2.94 million shsMarket Capitalization$801.09 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina. Read More Receive CMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMRX Stock News HeadlinesWhy Chimerix Inc. (CMRX) is Surging in 2025April 30, 2025 | msn.comJAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell?April 9, 2025 | msn.comA 17-year investing experiment investigated in DublinPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 20 at 1:00 AM | Porter & Company (Ad)Is Chimerix Inc. (CMRX) the Best Performing NASDAQ Stock So Far in 2025?April 2, 2025 | msn.comChimerix Inc. (NASDAQ:CMRX) Amazing Performance So Far In 2025March 26, 2025 | msn.comChimerix reports Q4 EPS (25c), consensus (28c)March 22, 2025 | markets.businessinsider.comChimerix Reports Fourth Quarter and Year End 2024 Financial ResultsMarch 21, 2025 | globenewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of ShareholdersMarch 14, 2025 | morningstar.comMSee More Headlines CMRX Stock Analysis - Frequently Asked Questions How were Chimerix's earnings last quarter? Chimerix, Inc. (NASDAQ:CMRX) posted its earnings results on Friday, March, 21st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.01. The biopharmaceutical company earned $0.06 million during the quarter, compared to the consensus estimate of $0.31 million. When did Chimerix IPO? Chimerix (CMRX) raised $102 million in an initial public offering (IPO) on Thursday, April 11th 2013. The company issued 7,320,000 shares at a price of $13.00-$15.00 per share. What other stocks do shareholders of Chimerix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Chimerix investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Pfizer (PFE) and Broadcom (AVGO). Company Calendar Last Earnings3/21/2025Today5/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMRX CIK1117480 Webwww.chimerix.com Phone(919) 806-1074Fax919-806-1146Employees90Year Founded2000Profitability EPS (Trailing Twelve Months)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$82.10 million Net MarginsN/A Pretax Margin-52,574.85% Return on Equity-50.78% Return on Assets-44.94% Debt Debt-to-Equity RatioN/A Current Ratio6.33 Quick Ratio6.33 Sales & Book Value Annual Sales$212 thousand Price / Sales3,778.71 Cash FlowN/A Price / Cash FlowN/A Book Value$2.17 per share Price / Book3.94Miscellaneous Outstanding Shares93,804,000Free Float78,154,000Market Cap$801.09 million OptionableNo Data Beta-0.17 Social Links 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:CMRX) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredAre we ignoring the same signal Wall Street ignored in 1929?In 1929, Irving Weiss spotted a systemic crisis hiding beneath record highs and shorted the market - turning $...Weiss Ratings | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chimerix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chimerix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
